TRC-766 is a negative control of RTC-5 (TRC-382). TRC-766 binds protein phosphatase 2A (PP2A) and does not activate the phosphatase.
In Vitro
As a pharmacologic control, the cells are treated with increasing doses of TRC-766, which is structurally similar to PP2A (SMAP) but biologically inactive. TRC-766 lacks a key N-H sulfonamide hydrogen bond donor. While TRC-766 still binds PP2A, it does not activate the phosphatase and therefore it was postulated to not affect cell viability. MCE has not independently confirmed the accuracy of these methods. They are for reference only.